What Happened?
Cambridge, MA-based Enzyvant Appointed Andrew Dawson as Senior Vice President of Human Resources
About the Company
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
About the Person
Andrew Dawson is Chief Human Resources Officer at Cedilla Therapeutics. Previously, Andrew held various senior HR leadership roles in the industry.
Info Source
News
Short Profile